Evommune (EVMN) News Today $22.74 -0.81 (-3.46%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$22.90 +0.16 (+0.70%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVMN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In GrowthMay 11, 2026 | finance.yahoo.comEvommune (NYSE:EVMN) Rating Increased to Hold at Wall Street ZenMay 10, 2026 | marketbeat.comEvommune Highlights Q1 Results and Advancing Inflammation PipelineMay 7, 2026 | tipranks.comEvommune Reports First Quarter 2026 Financial Results and Provides Business HighlightsMay 7, 2026 | businesswire.comWall Street Zen Downgrades Evommune (NYSE:EVMN) to SellMay 2, 2026 | marketbeat.comEvommune (NYSE:EVMN) Coverage Initiated by Analysts at Stifel NicolausMay 1, 2026 | marketbeat.comEvommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Buy" from BrokeragesApril 30, 2026 | marketbeat.comEvommune, Inc.'s (NYSE:EVMN) Lock-Up Period To Expire on May 5thApril 28, 2026 | marketbeat.comEvommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic DermatitisApril 26, 2026 | theglobeandmail.comStocks to watch: Evommune sees RS rating jump to 91April 20, 2026 | msn.comEvommune Spotlights EVO756 as Novel Preventive Migraine TherapyApril 15, 2026 | theglobeandmail.comEvommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention TranscriptApril 14, 2026 | seekingalpha.comEvommune earns relative strength rating upgradeApril 9, 2026 | msn.comStocks to watch: Evommune sees RS rating rise to 85March 26, 2026 | msn.comClear Street initiates coverage of Evommune (EVMN) with buy recommendationMarch 19, 2026 | msn.comStocks to watch: Evommune sees RS rating rise to 91March 18, 2026 | msn.comEvommune: Buy Rating Backed by 2026 Catalyst Rich Pipeline and Differentiated MRGPRX2 Dermatology FranchiseMarch 18, 2026 | tipranks.com1 under-the-radar biotech to buy for potential 10x growth in the next decadeMarch 10, 2026 | msn.comEvommune, Inc. (EVMN) Receives a Rating Update from a Top AnalystMarch 7, 2026 | theglobeandmail.comStocks showing improving market leadership: Evommune earns 83 RS ratingMarch 6, 2026 | msn.comEvommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business HighlightsMarch 5, 2026 | finance.yahoo.comEvommune Reports Q4 2025 Results and Pipeline ProgressMarch 5, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Charles River Labs (CRL)February 20, 2026 | theglobeandmail.comAssessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m PlacementFebruary 14, 2026 | finance.yahoo.comEvommune Announces $125 Million Private PlacementFebruary 12, 2026 | businesswire.comEvommune Stock Cools Off After Big Rally On Successful Eczema TrialFebruary 12, 2026 | benzinga.comEvommune's EVO301 Phase 2a Data Drives 70% Stock SurgeFebruary 11, 2026 | seekingalpha.comObjectif de cours d’Evommune relevé à 55$ par Evercore ISI suite à des données positivesFebruary 10, 2026 | fr.investing.comEvommune's stock surges on strong results for new eczema drugFebruary 10, 2026 | msn.comLe titre d’Evommune s’envole après des résultats positifs d’essais de phase 2a pour son médicament contre l’eczémaFebruary 10, 2026 | fr.investing.comLe médicament d’Evommune contre la dermatite atopique atteint son objectif principal dans un essai de phase 2aFebruary 10, 2026 | fr.investing.comEvommune stock soars after positive Phase 2a trial results for eczema drugFebruary 10, 2026 | in.investing.comThis Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?February 10, 2026 | msn.comEvommune surges on mid-stage trial win for eczema therapyFebruary 10, 2026 | msn.comEvommune Advances EVO301 After Positive Phase 2a ResultsFebruary 10, 2026 | tipranks.comEvommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic DermatitisFebruary 10, 2026 | businesswire.comOppenheimer initiates coverage of Evommune (EVMN) with outperform recommendationJanuary 23, 2026 | msn.comHigh Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 (EVMN)2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.January 19, 2026 | marketbeat.comL’action Evommune initiée avec une recommandation d’achat par H.C. Wainwright pour son potentiel contre l’urticaireJanuary 6, 2026 | fr.investing.comEvommune participates in a conference call with William BlairJanuary 6, 2026 | msn.comEvommune (NYSE:EVMN) Director Buys $17,350.00 in StockDecember 23, 2025 | insidertrades.comHopfner achète des actions Evommune (EVMN) d’une valeur de 17.350$December 22, 2025 | fr.investing.comBuy Rating for Evommune, Inc. Driven by EVO756’s Promising Phase II Trial PotentialDecember 15, 2025 | tipranks.comEvommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy RatingDecember 12, 2025 | tipranks.comEvommune reports Q3 EPS ($8.07) vs ($10.47) last yearDecember 11, 2025 | msn.comEvommune Reports Third Quarter 2025 Financial Results and Provides Business UpdateDecember 11, 2025 | businesswire.comEvommune Aims For IPO In Bifurcated Biopharma MarketOctober 14, 2025 | seekingalpha.com Get Evommune News Delivered to You Automatically Sign up to receive the latest news and ratings for EVMN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVMN Media Mentions By Week EVMN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EVMN News Sentiment▼0.000.55▲Average Manufacturing News Sentiment EVMN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EVMN Articles This Week▼03▲EVMN Articles Average Week Get the Latest News and Ratings for EVMN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Evommune and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BEAM News Today ERAS News Today ORKA News Today ALMS News Today RCUS News Today DNLI News Today DYN News Today VERA News Today TARS News Today ARQT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:EVMN) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evommune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evommune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
